The Angiotensin-I Converting Enzyme Gene I/D Variation Contributes to End-Stage Renal Disease Risk in Chinese Patients with Type 2 Diabetes Receiving Hemodialysis.
Ming Lu,Jianzhong Zhang,Ming Li,Xiaoxu Ge,Xu Dai,Jiao Zhao,Mingzhou Fu,Tao Wang,Xiyao Fang,Can Li,Rong Zhang,Weijing Zhao,Taishan Zheng,Feng Wang,Ming Yu,Tao Lei,Niansong Wang,Yuqian Bao,Limei Liu,Yanjun Liu,Weiping Jia
DOI: https://doi.org/10.1007/s11010-016-2819-6
IF: 3.842
2016-01-01
Molecular and Cellular Biochemistry
Abstract:Whether the DD genotype of the angiotensin-I converting enzyme (ACE) I/D variation contributes to end-stage renal disease (ESRD) risk in type 2 diabetes mellitus (T2DM) remains controversial. Differences in study design, case and control definition, sample size and ethnicity may contribute to the discrepancies reported in association studies. We performed a case–control study to evaluate the association of the ACE I/D variation with ESRD risk in Chinese patients with T2DM receiving hemodialysis and analyzed the genotype–phenotype interaction. Unrelated Chinese patients (n = 432) were classified into the non-diabetic nephropathy (DN) control group (n = 222, duration of diabetes >10 years, no signs of renal involvement) and the DN-ESRD group (n = 210; ESRD due to T2DM, receiving hemodialysis). Polymerase chain reaction was used to genotype ACE I/D for all 432 subjects. The frequencies of the ID + DD genotypes were higher in the DN-ESRD group than non-DN control group (65.2 vs. 50.9 %; adjusted OR 1.98 (95 % CI, 1.31–3.00; P = 0.001). In the DN-ESRD group, the DD genotypic subgroup had significantly elevated HbA1c and diastolic blood pressure (DBP) compared to the II subgroup (both P < 0.05). The DD genotype of the ACE I/D variation may be associated with more elevated blood pressure and HbA1c, and therefore may predict the development, progression and severity of DN-ESRD in Chinese patients with T2DM undergoing hemodialysis.